Physician

Leonard Thomas Hackett, M.D.

According to 2025 Medicare claims, Leonard Hackett, M.D. (NPI: 1669466868) practices hematology in the Fresno, CA market, with the plurality of this provider's patient population coming from Fresno, CA. This provider's primary affiliated billing organization is CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (NPI: 1083661607; TIN: 770324589) and primary practice location at 93720-3347.

Hackett's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,248 traditional Medicare patients, billed 344,270 HCPCS/CPT codes, and received $5,609,998 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,624 prescription claims across 228 beneficiaries totaling $3,972,539 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 138 claims. Open Payments data shows 60 records totaling $1,428. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $3,663,152 to $5,609,998. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,168,704 to $3,972,539. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $8,212 to $2,102.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	786	322,151	$3,663,152
2016	802	444,769	$3,248,646
2017	788	326,521	$3,011,941
2018	800	313,407	$3,772,420
2019	839	354,915	$3,456,850
2020	1,117	382,830	$4,498,648
2021	1,150	406,737	$5,354,354
2022	1,103	355,035	$4,745,942
2023	1,194	409,553	$5,646,577
2024	1,248	344,270	$5,609,998

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	216	1,512	$2,168,704
2016	202	1,580	$2,558,608
2017	199	1,344	$2,352,614
2018	196	1,524	$3,458,961
2019	212	1,535	$4,271,701
2020	222	1,682	$4,098,348
2021	233	1,682	$4,636,357
2022	238	1,629	$5,072,821
2023	237	1,704	$4,137,192
2024	228	1,624	$3,972,539

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	177	$50,578
2016	N/R	80	$5,528
2017	N/R	12	$986
2018	N/R	N/R	N/R
2019	N/R	13	$1,208
2020	N/R	14	$1,702
2021	N/R	11	$1,782
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	138	$83,427

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	612	1,768	$97
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	401	857	$13
80053	Blood test, comprehensive group of blood chemicals	607	2,612	$10
36415	Insertion of needle into vein for collection of blood sample	637	2,883	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	611	2,904	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	51	1,530	$910,360
Pomalyst	Pomalidomide	26	717	$469,637
Xtandi	Enzalutamide	29	855	$360,048
Lenalidomide	Lenalidomide	20	560	$269,438
Erleada	Apalutamide	22	660	$266,317

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4197	Parenteral nutrition solution; compounded amino acid and carbohydrates with electrolytes, trace elements and vitamins, including preparation, any strength, 74 to 100 grams of protein - premix	N	N/R	35	$71,445
B4224	Parenteral nutrition administration kit, per day	N	N/R	36	$6,526
B4185	Parenteral nutrition solution, not otherwise specified, 10 grams lipids	N	N/R	31	$3,368
B4220	Parenteral nutrition supply kit; premix, per day	N	N/R	36	$2,089

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	60	$1,428	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Leonard Thomas Hackett, M.D.?

Tedicare shows public-source Medicare data for Leonard Thomas Hackett, M.D. (NPI 1669466868), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Leonard Thomas Hackett, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Leonard Thomas Hackett, M.D.?

Leonard Thomas Hackett, M.D. is linked to CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (billing NPI 1083661607) in the available physician profile data.

Does Leonard Thomas Hackett, M.D. have Open Payments data?

Leonard Thomas Hackett, M.D. has 60 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.